KR20210153642A - 바이러스 및 박테리아 감염 치료를 위한 신규 mek-억제제 - Google Patents

바이러스 및 박테리아 감염 치료를 위한 신규 mek-억제제 Download PDF

Info

Publication number
KR20210153642A
KR20210153642A KR1020217036169A KR20217036169A KR20210153642A KR 20210153642 A KR20210153642 A KR 20210153642A KR 1020217036169 A KR1020217036169 A KR 1020217036169A KR 20217036169 A KR20217036169 A KR 20217036169A KR 20210153642 A KR20210153642 A KR 20210153642A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
virus
infection
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217036169A
Other languages
English (en)
Korean (ko)
Inventor
올리버 플란츠
Original Assignee
아트리바 테라퓨틱스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아트리바 테라퓨틱스 게엠베하 filed Critical 아트리바 테라퓨틱스 게엠베하
Publication of KR20210153642A publication Critical patent/KR20210153642A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020217036169A 2019-04-16 2020-04-16 바이러스 및 박테리아 감염 치료를 위한 신규 mek-억제제 Pending KR20210153642A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LULU101183 2019-04-16
LU101183A LU101183B1 (en) 2019-04-16 2019-04-16 Novel mek-inhibitor for the treatment of viral and bacterial infections
PCT/EP2020/060692 WO2020212478A1 (en) 2019-04-16 2020-04-16 Novel mek-inhibitor for the treatment of viral and bacterial infections

Publications (1)

Publication Number Publication Date
KR20210153642A true KR20210153642A (ko) 2021-12-17

Family

ID=66554457

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217036169A Pending KR20210153642A (ko) 2019-04-16 2020-04-16 바이러스 및 박테리아 감염 치료를 위한 신규 mek-억제제

Country Status (13)

Country Link
US (1) US12350244B2 (https=)
EP (1) EP3955908B1 (https=)
JP (2) JP2022529343A (https=)
KR (1) KR20210153642A (https=)
CN (1) CN114007598A (https=)
AU (1) AU2020258002B2 (https=)
BR (1) BR112021020605A2 (https=)
CA (1) CA3136171A1 (https=)
EA (1) EA202192454A1 (https=)
ES (1) ES3012533T3 (https=)
LU (1) LU101183B1 (https=)
MX (1) MX2021012604A (https=)
WO (1) WO2020212478A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3912623B1 (en) * 2020-05-20 2024-07-31 Atriva Therapeutics GmbH Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm
EP4186500A1 (en) * 2021-11-24 2023-05-31 Atriva Therapeutics GmbH Mek inhibitors for the prevention and treatment of long covid syndrome
WO2024042050A1 (en) * 2022-08-22 2024-02-29 Atriva Therapeutics Gmbh Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs
CN119931962B (zh) * 2025-04-07 2025-08-05 北京华诺泰生物医药科技有限公司 一种人偏肺病毒的培养方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040237A1 (en) * 1999-01-07 2000-07-13 Warner-Lambert Company Antiviral method using mek inhibitors
KR20020012315A (ko) * 1999-07-16 2002-02-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법
DE10017480A1 (de) 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
WO2014056894A1 (en) 2012-10-08 2014-04-17 Westfaelische Wilhelms-Universitaet Muenster Mek inhibitors in the treatment of virus diseases
CN113398271A (zh) 2014-05-16 2021-09-17 归属疗法有限公司 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略
EP3973960B1 (en) * 2017-10-17 2025-09-03 Atriva Therapeutics GmbH Novel mek-inhibitor for the treatment of viral and bacterial infections
KR20220074869A (ko) * 2019-08-27 2022-06-03 아트리바 테라퓨틱스 게엠베하 Mek 억제제와 캡-의존성 엔도뉴클레아제 억제제의 조합
JP7802365B2 (ja) * 2019-10-08 2026-01-20 アトリバ セラピューティクス ゲーエムベーハー ハンタウイルス感染症の処置のためのｍｅｋ阻害剤
EP3912623B1 (en) * 2020-05-20 2024-07-31 Atriva Therapeutics GmbH Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm

Also Published As

Publication number Publication date
JP2025124703A (ja) 2025-08-26
EA202192454A1 (ru) 2022-03-22
JP2022529343A (ja) 2022-06-21
LU101183B1 (en) 2020-10-16
CA3136171A1 (en) 2020-10-22
CN114007598A (zh) 2022-02-01
US20220193017A1 (en) 2022-06-23
AU2020258002B2 (en) 2025-12-18
AU2020258002A1 (en) 2021-11-18
ES3012533T3 (en) 2025-04-09
BR112021020605A2 (pt) 2021-12-07
EP3955908A1 (en) 2022-02-23
MX2021012604A (es) 2021-11-12
US12350244B2 (en) 2025-07-08
WO2020212478A1 (en) 2020-10-22
EP3955908C0 (en) 2025-01-22
EP3955908B1 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
JP7618276B2 (ja) ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤
KR20210153642A (ko) 바이러스 및 박테리아 감염 치료를 위한 신규 mek-억제제
KR102174576B1 (ko) 바이러스 질환 치료에서의 ｍｅｋ 억제제
US20220370384A1 (en) Combinations of mek inhibitors with cap-dependent endonuclease inhibitors
JP2023529025A (ja) 抗ウイルス処置としてのアゼラスチン
EA047137B1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
HK40029715B (en) Novel mek-inhibitor for the treatment of viral and bacterial infections
HK40029715A (en) Novel mek-inhibitor for the treatment of viral and bacterial infections
BR112020007442B1 (pt) Uso de PD-0184264 ou um sal farmaceuticamente aceitável do mesmo e composições farmacêuticas
EA042391B1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000